Today: 23 January 2026
Subscribe
Browse Category

KRX:005490 News 19 January 2026 - 23 January 2026

PLS Group share price sticks near a 52-week high — what traders watch next week

PLS Group share price sticks near a 52-week high — what traders watch next week

Sydney, Jan 23, 2026, 16:49 AEDT — Market closed PLS Group Limited shares (ASX:PLS) closed Friday at A$5.08, up 0.8%, reaching an intraday high of A$5.16 — their highest level in 52 weeks. (Investing) The stock remains locked onto the lithium rally. Prices for this key battery metal have picked up, pulling investors back toward names that struggled through much…
23 January 2026
·······
PLS share price whipsaws as lithium traders eye Jan 30 quarterly update

PLS share price whipsaws as lithium traders eye Jan 30 quarterly update

SYDNEY, Jan 19, 2026, 16:51 AEDT — The market has closed. PLS Group Ltd (PLS.AX) closed modestly up on Monday, recovering from an early dip as investors digested new shifts in lithium feedstock prices and braced for a wave of quarterly reports in the sector. The shares finished at A$4.69, a 0.1% gain, after swinging between A$4.49 and A$4.69, with…
19 January 2026
······

Stock Market Today

  • AngioDynamics (ANGO) Stock Shows 81.88% Upside Despite Profitability Challenges
    January 23, 2026, 8:39 AM EST. AngioDynamics, Inc. (NASDAQ: ANGO) offers an 81.88% potential upside with an average analyst target price of $19.33, driven by three buy ratings and zero sell or hold recommendations. The New York-based medical device firm specializes in treating peripheral vascular disease and oncology, with a current market cap of $438.14 million and stock price at $10.63. However, the company faces profitability hurdles, reflected in a negative forward P/E of -96.64, a -0.67 EPS, and a -15.26% return on equity. Revenue grew 9%, and free cash flow remains positive at $300,625, signaling operational strength. Technical signals are mixed: oversold RSI at 17.38 hints at rebound potential, while negative MACD suggests short-term weakness. Investors should balance the growth promise of products like Auryon and AlphaVac against financial and market risks.
Go toTop